Have Insiders Sold Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Recently?

By
Simply Wall St
Published
May 07, 2022
NasdaqGS:KPTI
Source: Shutterstock

We'd be surprised if Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shareholders haven't noticed that the President, Richard Paulson, recently sold US$178k worth of stock at US$6.23 per share. On the bright side, that sale was only 4.3% of their holding, so we doubt it's very meaningful, on its own.

Check out our latest analysis for Karyopharm Therapeutics

The Last 12 Months Of Insider Transactions At Karyopharm Therapeutics

In fact, the recent sale by Richard Paulson was the biggest sale of Karyopharm Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at around the current price of US$6.08. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

In the last year Karyopharm Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGS:KPTI Insider Trading Volume May 7th 2022

I will like Karyopharm Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Does Karyopharm Therapeutics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Karyopharm Therapeutics insiders own 2.0% of the company, worth about US$9.8m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

What Might The Insider Transactions At Karyopharm Therapeutics Tell Us?

Insiders sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Karyopharm Therapeutics has 5 warning signs (1 can't be ignored!) that deserve your attention before going any further with your analysis.

Of course Karyopharm Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.